OBJECTIVE: @entity784 ( @entity784 ), primarily developed to prevent @entity2132 ( @entity2132 ), might reduce early @entity409 after allogeneic hematopoietic stem cell transplantation. However, no comparative studies have been performed to investigate this. We analyzed the influence of selection for @entity2280 (+) cells on the incidence and severity of @entity5501 ( @entity5501 ). @entity1 AND METHODS: Five hundred and one @entity1 who underwent allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical siblings were included in the present study. Two hundred and ninety @entity1 (59%) were grafted with @entity2280 + positively selected grafts and 211 (41%) with nonmanipulated grafts. Their mean age was 38 years (range 17-63). All @entity1 had @entity1583 and 96% were conditioned with combinations either of @entity786 plus total-body irradiation or of @entity786 plus busulphan. Most of the @entity1 received @entity2132 prophylaxis with @entity1499 ( @entity1500 ) or @entity205 . RESULTS: Fifty-two @entity1 (10.4%) developed @entity5501 . @entity5501 was more frequent in @entity1 receiving nonmanipulated grafts (16.1% vs 6.2%; p<0.0009), in those with a Karnofsky score less than 90 (17.5% vs 7.8%; p=0.001), and with the use of @entity1500 for @entity2132 prophylaxis (14.8% vs 7%; p=0.005). In multivariate analyses, only @entity2280 + positive selection (p=0.0007) and Karnofsky score (p=0.004) emerged as independent risk factors for @entity5501 . The same effect was observed in the subset of @entity1 with severe @entity5501 . CONCLUSION: These findings show that @entity2280 + selection not only decreases the incidence of @entity2132 but also prevents @entity5501 after HLA-identical sibling PBSCT.

Positive selection for XXXX + reduces the incidence and severity of @entity5501 after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity784 :: ('MESH:D016399', 'Disease') :: ['T-cell depletion', 'TCD'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver dysfunction'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin A'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft-vs-host disease'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematological malignancies'] @entity5501 :: ('MESH:D006504', 'Disease') :: ['hepatic veno-occlusive disease', 'VOD'] @entity1500 :: ('CHEBI:44185', 'Chemical') :: ['MTX'] @entity2280 :: ('947', 'Gene') :: ['CD34'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity2280 :: (947,Gene) :: ['CD34']
